UCB: UCB’s new organisation to focus on four units

NEUTRAL, Fair Value EUR42 (-2%)

News published on February Tuesday 5, 2013
Share on
UCB has announced this morning that it is to adapt its organisational structure in order to better align it with platform growth: Core medicines Cimzia, Vimpat and Neupro are expected to achieve combined peak sales of at least EUR3.1bn according to the company (BG est: EUR2.8bn in 2021), emerging markets, late stage pipeline, to deliver breakthrough medicines into the pipeline and deliver on competitive company profitability.

Full report available to subscribers
Please contact marketing@bryangarnier.fr

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities